Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04398823
Other study ID # XH-20-006
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date May 15, 2020
Est. completion date December 31, 2021

Study information

Verified date April 2020
Source Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Contact Feng Shen
Phone 18202159980
Email shenfeng01@xinhuamed.com.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

"Internal hemorrhoid" affects the quality of life due to hemorrhage and prolapse as a common and frequently-occurring disease. Endoscopic sclerosing agent injection has replaced traditional surgery and become the most commonly used treatment method in developed countries. At present, how to reduce the side effects of sclerosing agent and accurately determine the injection site and depth has become a difficult clinical problem. The research group creatively put forward the theory of foam sclerosing agent to treat internal hemorrhoids in the early stage. With the aid of transparent cap, the visibility of surgical field of vision can be improved. The mini probe ultrasound (MPS) is proposed to effectively evaluate the submucosal in


Recruitment information / eligibility

Status Recruiting
Enrollment 700
Est. completion date December 31, 2021
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- People are willing to sign the informed consent form of this trial.

- People(aged 18 to 70 years) with clinical symptoms such as bleedingprolapse and so on have been diagnosed with grade I, grade II and grade III internal hemorrhoids by colonic epdoscopy;

- People can follow short-term (3 month) and long-term (12 month) visit plans;

- Describe symptoms objectively and actively complete the evaluation scale;

- No allergic diseases and allergy to sclerosing drugs;

- Non-lactating and pregnant women: patients without pregnancy plan (including the men) in 1 month after the test;

- Did not participate in any drug trials (including this trial drug) within 3 months before the trial;

- People with long-term use of anticoagulant drugs (such as aspirin, clopidogrel, etc.) need to be stopped for 5-7 day

Exclusion Criteria:

- People with severe insufficiency of heart, brain, lung and other organs, leading to inability to tolerate endoscopic treatment;

- People with drug allergies or abnormal blood coagulation function;

- People suffering from or combined with digestive tract diseases,such as the colon malignancyulcerative colitis or Crohn's diseaseacute diarrheaacute thrombotic internal hemorrhoids with painanal fistulaanal fissurefecal incontinence

- Men with history of severe prostate hypertrop;

- People with any reasons that the researchers believe can not be selected

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sclerosing foam of Lauromacrogol
Participants in FS will receive enteroscopy with the sclerosing foam of lauromacrogol.
Sclersing liqiud of Lauromacrogol
Participants in LS will receive enteroscopy with the sclerosing liquid of lauromacrogol.

Locations

Country Name City State
China Xinhua Hospital,Shangha Jiao Tong University Shanghai

Sponsors (14)

Lead Sponsor Collaborator
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Anhui Provincial Hospital, Changzhi People's Hospital, Ganzhou Fifth pepole's Hospital, Jiangsu Provincial Second Chinese Medicine Hospital, Luoyang Central Hospital, Nanjing PLA General Hospital, Shandong Maternal and Chidl Care Service Center, Shanghai Construction Group Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, The First Affiliated Hospital of Zhengzhou University, The First Hospital of Anhui Medical University, Tongren Hospital,Shanghai Jiao Tong University School of Medicine, West China Forth University Hospital,Sichuan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the condition of bleeding?perianal pruritus ?the degree of prolapse of internal hemorrhoids and the influence of internal hemorrhoids by self-assessment. After 12 months,all the participants will receive the telephone follow-up to record their self-assessment. 12 months
Primary the condition of perianal pruritus?the description of hemorrhoids(include the number and depth of hemorrhoids)?the need for additiongal sclerotherapy under colonic endoscopy. after 12 months ,all the participants will receive the colonic endoscopy and we will record the degree of prolapse of internal hemorrhoids?the numbers of hemorrhoid under colonic endoscopy. 12 months
Secondary the condition of participants' bleeding?perianal pain and perianal pruritus after the endoscopic treatment. one day after receiving endoscopic treatment , all the participants will receive the telephone follow-up and we will record their self-assessment,include the condition of bleeding?perianal pain and perianal pruritus. 1 day
Secondary the condition of bleeding?perianal pruritus ?the degree of prolapse of internal hemorrhoids and the influence of internal hemorrhoids by self-assessment. After 3 months,all the participants will receive the telephone follow-up to record their self-assessment. 3 months
Secondary the condition of participants' bleeding?perianal pain and perianal pruritus after the endoscopic treatment. one week after receiving endoscopic treatment , all the participants will receive the telephone follow-up and we will record their self-assessment,include the condition of bleeding?perianal pain and perianal pruritus. 1 week
Secondary the condition of perianal pruritus?the description of hemorrhoids(include the number and depth of hemorrhoids)?the need for additiongal sclerotherapy under colonic endoscopy. after 3 months ,all the participants will receive the colonic endoscopy and we will record the degree of prolapse of internal hemorrhoids?the numbers of hemorrhoid under colonic endoscopy. 3 months